NovoMedix Presents New Preclinical Data on NMX2 at the 2022 American Heart Association (AHA) Scientific Sessions Meeting
SAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- NovoMedix, LLC ("NovoMedix"), a biotechnology company developing novel, multi-pathway modulators for ...
NovoMedix Receives Research Grant from the National Institutes of Health (NIH) to Advance NMX1 in TNBC
NovoMedix, LLC ("NovoMedix"), a biotechnology company creating novel, safe, and effective drugs to treat unmet ...
October 20, 2020
Novel Dual MTOR Inhibitor/AMPK Activator Mitigates Doxorubicin Cardiotoxicity And Potentiates Its Chemotherapeutic Efficacy Against Triple Negative Breast Cancer”, Scientific Sessions 2020
April 26, 2020
Synergistic anti-metastatic effect of pembrolizumab in combination with a novel mTORC1 inhibitor/AMPK agonist in a CAM metastatic triple negative breast cancer model, Virtual AACR 2020 Annual Meeting
“Novel Dual MTOR Inhibitors/AMPK Activators Attenuate Doxorubicin-induced Cardiotoxicity” Rapid Fire Oral Presentation in American Heart Association Scientific Sessions
A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure, American Journal of Physiology Heart and Circulatory Physiology
AHA 2022 Meeting
The premier global event focusing on improving health by championing scientific discovery and practice-changing educational content.
Life Sciences Summit (LSS)
The conference features corporate presentations by promising young companies with transformative science that targets unmet medical needs.
Highlights the work of the best minds in research and medicine from institutions all over the world.